Quercetin

Bioavailability matters enormously for quercetin. Standard quercetin aglycone has only 2-10% oral bioavailability because of poor water solubility and rapid hepatic conjugation. For most clinical uses, prefer a bioavailability-enhanced form: EMIQ (enzymatically modified isoquercitrin, alpha-glycosyl isoquercitrin) provides 5-10-fold higher plasma levels; quercetin phytosome (Quercefit from Indena) provides up to 20-fold higher plasma levels. The price premium is worth it because many clinical effects require plasma concentrations that unenhanced aglycone supplements struggle to achieve. Look for specific form labeling (EMIQ, Quercefit, phytosome, alpha-glycosyl isoquercitrin) rather than just 'quercetin 500 mg' which typically means standard aglycone.

Yes, modestly. Serban 2016 meta-analysis (PMID 27405810) pooled 7 randomized controlled trials and found quercetin supplementation reduced systolic blood pressure by 3.0 mmHg and diastolic by 2.6 mmHg in hypertensive subjects. Edwards 2007 (PMID 17951477) specifically tested 730 mg daily in stage 1 hypertensive men and found reductions of 7 mmHg systolic and 5 mmHg diastolic after 28 days. The effect emerges over 4-8 weeks, requires doses of 500 mg daily or higher, and is larger in hypertensive subjects than in normotensive subjects. Quercetin is most useful as an adjunct to lifestyle measures or alongside first-line antihypertensive therapy, not as a replacement for prescription medication in moderate or severe hypertension.

Yes, through mast cell stabilization and histamine release inhibition. Typical allergy dosing is 500 mg two to three times daily of a bioavailability-enhanced form, often combined with bromelain 200-500 mg per dose and vitamin C 500 mg daily. Begin 4-6 weeks before expected allergy season for prophylactic benefit. Multiple small trials and a 2020 review (Jafarinia PMID 32407321) support allergic rhinitis symptom reduction. Quercetin is not a first-line replacement for antihistamines in severe allergic disease but is useful as adjunctive therapy, particularly for patients seeking a non-drowsy option or combination approach. The effect is additive with H1/H2 antihistamines and nasal corticosteroids.

D+Q refers to dasatinib plus quercetin, a senolytic combination developed by Kirkland's group at Mayo Clinic (Zhu 2015 PMID 25754370). It selectively induces apoptosis in senescent cells while sparing normal cells. Typical dosing in clinical trials is dasatinib 100 mg plus quercetin 1000 mg daily for 3 CONSECUTIVE DAYS administered monthly or quarterly. This is an INTERMITTENT high-dose pulse rather than continuous daily use. Dasatinib is a prescription tyrosine kinase inhibitor with significant side effects (myelosuppression, edema, QT prolongation, bleeding, drug interactions) and should NEVER be self-administered. Active clinical trials are ongoing in idiopathic pulmonary fibrosis (LaPP trial), Alzheimer's disease, diabetic kidney disease (Hickson 2019 PMID 31542391 pilot), osteoarthritis, and frailty. Patients interested in senolytic approaches should consider trial participation or alternative natural senolytic strategies (fisetin 20 mg/kg for 2 days monthly).

Generally yes at typical doses, but several drug interactions require attention. AVOID with cyclosporine (substantially increases cyclosporine levels). Use caution with warfarin (monitor INR), digoxin (monitor level), fluoroquinolone antibiotics (time-separate by 2-4 hours or avoid during active courses), and tyrosine kinase inhibitor chemotherapy (specialist supervision required). Moderate interactions with CYP3A4-metabolized statins and some chemotherapy agents. Separate from iron supplementation by 2-4 hours to avoid chelation. Discontinue 2 weeks before scheduled surgery due to mild antiplatelet effect. Most common medications (metformin, SSRIs, thyroid hormone, oral contraceptives, asthma inhalers) have no clinically significant interaction. Review medication list with a knowledgeable clinician when starting quercetin supplementation.

For general antioxidant and cardiovascular benefits, dietary intake may be adequate with emphasis on quercetin-rich foods: red onions (20-50 mg per 100 g, especially the outer rings), capers (180-230 mg per 100 g — densest source), apples with peel (4-10 mg per medium apple), berries (blueberries 2-8 mg, cranberries 15-25 mg, blackcurrants 12-16 mg per 100 g), kale, broccoli, green tea, and buckwheat. A Mediterranean-style diet provides 15-40 mg quercetin daily. For specific clinical endpoints (blood pressure reduction, allergic rhinitis symptom management, senolytic effect), dietary intake is generally insufficient and supplementation at 500-1500 mg daily of a bioavailability-enhanced form is more likely to produce meaningful effect. Dietary intake supports baseline polyphenol diversity; supplementation provides dose-response clinical applications.

The evidence is preliminary and the clinical significance is contested. The mechanistic rationale is sound: quercetin is a zinc ionophore (Dabbagh-Bazarbachi 2014 PMID 25402583) and zinc inhibits viral RNA-dependent RNA polymerase. Di Pierro 2021 (PMID 33853179) tested Quercefit quercetin phytosome 1000 mg daily in 152 mildly symptomatic COVID-19 outpatients and reported reduced hospitalization rates and shorter viral clearance. However, the trial was not blinded and methodological limitations have been noted. The FDA has not approved quercetin for COVID-19 treatment or prevention, and major professional societies do not recommend it as an evidence-based intervention. If used, quercetin 1000 mg daily of phytosome form combined with zinc 15-30 mg daily, vitamin C 500-1000 mg, and vitamin D3 2000-5000 IU is a reasonable prophylactic approach with favorable safety but uncertain efficacy. Does not replace vaccination, masking, or evidence-based antiviral therapy in active COVID-19.

Both are flavonoid senolytic candidates with overlapping mechanisms. Fisetin (fisetin) has better oral bioavailability than quercetin aglycone, crosses the blood-brain barrier more efficiently, and has stronger in vitro senolytic activity than quercetin alone. Fisetin is typically used at 20 mg/kg for 2 consecutive days monthly as a standalone protocol (Yousefzadeh 2018 PMID 30213834 in mice; human pilot trials ongoing). Quercetin is typically used as half of the D+Q combination with prescription dasatinib, which amplifies the senolytic effect substantially above quercetin alone. For self-administered natural senolytic protocols without prescription requirements, fisetin is generally the more established choice. Quercetin may be added during fisetin senolytic days for additive effect. The D+Q combination remains the specialist reference standard when available through medical supervision.

Quercetin has a favorable safety profile. The most common side effects are mild gastrointestinal symptoms (nausea, loose stools, bloating) at doses above 1000 mg daily, usually mitigated by taking with food. Transient headache at initiation is occasionally reported. Rare reports of paresthesia at very high doses. No consistent signal of hepatic, renal, or hematologic toxicity at oral doses up to 1500 mg daily for 12 weeks. Drug interactions are the most important practical concern — particularly with cyclosporine (avoid), warfarin (monitor), and fluoroquinolone antibiotics (time-separate). Discontinue 2 weeks before surgery due to mild antiplatelet effect. Pregnancy safety at supplementation doses is uncharacterized; dietary intake is safe. At dietary intake levels through food, quercetin is universally safe.

Yes, at typical supplementation doses (500-1000 mg daily of a bioavailability-enhanced form) for indefinite duration. Studies up to 12 months at these doses have not identified safety concerns. Long-term use is appropriate for chronic indications like perennial allergic rhinitis, cardiovascular prevention, general polyphenol stacking, and metabolic health support. Higher doses (1500+ mg daily) are typically used for short-term specific indications rather than indefinite use. For very long-term use, periodic review of the supplementation rationale, medication list for emerging interactions, and clinical response assessment is prudent. No tolerance develops and no withdrawal effects on discontinuation. Pair long-term supplementation with continued dietary intake of quercetin-rich foods for optimal combined effect.